Tackling Regulatory Barriers: Solving Challenges in the Indian Pharmaceutical Industry
India duniya ke lagbhag 20% Generic dwao ki world demand ko poora krne ke lie, produce krne aur export krne vale desho me se ek hai. Jaise ki, iske upr lge kafi ilzam jaise ki ghtiya aur harmful drugs bnane ke lge hai, Indian pharmaceutical products ki safety aur quality ke prati iski chinta ko bda diya hai. India Dwaio ki Safety me aai kmi ke kafi sare karan hai.
Sbse bda karan hai sahi trike se regulation aur enforcement me kmi. The Drugs and Cosmetics Act, 1940, jo India me drugs regulation ko sanchalit krta hai, outdated ho chukka hai aur isme kuch important points jaise clinical trials, achi manufacturing ke trike aadi jaise shamil nhi kie gae hai. Is act ki enforcement sahi se nhi hui hai aur banti hui hai, jisme multiple authorities ke paas ativyapi kshetradhikar aur responsibilities ke sath kai pradhikaran shamil hai.
Iske ilawa resources ki kmi iska dusra karan hai. Manpower, infrastructure, funds aur technology ki shortage hai jo ek drungs bnane vali jga ki aur products ki achi inspection, testing, monitoring aur surveillance ke lie zruri hai.
India ke drug regulatory system me transparency ki bhi kmi dekhne ko milti hai. The Central Drugs Standard Control Organization (CDSCO), jo desh me dwaio ke sanchalak hai, public ya media ko iski processes ya activities ke bare me sufficient suchna nhi deta h.
Aage dekhe to India ki kuch pharmaceutical companies hai jo maape hue standards aur norms jo manufacturing, testing, labelling ke lie bnae gae hai unhe follow nahi krti hai. Ye companies kuch unethical practices me rujhi hui hai jaise ghatiya aur expired raw material use krna, jhootha data btana, aur documents me bdlaav krna jisse inhe khrcha km pdhe aur profit zada ho.
Aisi regulations ke kaafi bure prabhav dekhne ko mil skte hai. Poor quality ke aur unsafe drugs public ki health ko nuksan phuncha skte hai, treatment fail kr skti hai aur even maut bhi ho skti hai. Aisi regulation se logo ka Indian pharmaceutical products se vishwas uth jata hai jis se industry ki reputation aur global market me competitiveness pr prabhav pdh skta hai.
Is se international relations aur cooperation pr bhi effect pdhta hai.
In issues se niptne ke lie kafi sare steps uthae gae hai. Sbse pehle government ko the Drugs and Cosmetics Act, 1940 me kuch bdlaav krne honge, ta ke abhi jo chize sudharne vali hai use sudhara ja ske aur logo ki safety assure ki ja ske.
Dusra, ek single central authority ho jiske paas sufficient powers, resources, expertise ho jo in laws ya norms ko effectively regulate kr ske.
Tisra, Quality products bnana bhut zruri jo safe ho. Government ko rules and norms follow krne vale ko incentives, support aur guidance deni chahiye jisse vo motivate ho. Voluntary self-regulation aur quality certification schemes bhi chlai ja skti hai.
bhaarat mein davaon ke aparyaapt suraksha maanakon ke lie viniyaman kee kamee, aparyaapt sansaadhan, paaradarshita kee kamee aur dava kampaniyon ke beech gair-anupaalan jaise kaarakon ko jimmedaar thaharaaya ja sakata hai. in muddon ka saarvajanik svaasthy, aarthik vikaas, antarraashtreey sambandhon aur sahayog par gambheer prabhaav padata hai. in chunautiyon ka samaadhaan karane ke lie, sarakaar ko dava niyaamak dhaanche mein sanshodhan karana chaahie, niyaamak sanrachana ko suvyavasthit karana chaahie aur udyog ke bheetar gunavatta aur suraksha kee sanskrti ko badhaava dena chaahie.
#pharmaceuticals #indianpharmaceuticals #pharmaceuticallaws #governmentlaws #Health #technology #CDSCO #indianpharmaceuticalindustry #genericdwao #medicines #india #airrnews
